Bowel obstruction due to semaglutide

Bowel obstruction due to semaglutide video

According to recent studies the use of GLP-1 agonists which include brands like Wegovy, Ozempic, and Rybelsus, was associated with the risk of bowel obstruction, a severe disorder where food can't pass through the small intestine. Now that these drugs are heavily promoted on social media and commonly used not only to treat type 2 diabetes but also for weight management purposes, we can expect more diagnoses of bowel obstruction to surface. If you've been diagnosed with bowel obstruction after using Ozempic, Wegovy, or Rybelsus, we strongly advise you to contact our attorneys, who might be able to help you file a claim.

Claim Application

Popular weight loss drugs associated with bowel obstruction

While the most common causes of bowel obstruction include nonfood objects swallowed on purpose or accidentally, abdominal surgery and several diseases, it was recently found that semaglutide, the active agent in some type 2 diabetes medications, may also lead to the development of this severe disorder. Therefore, if you are experiencing any of these symptoms - nausea, vomiting, bloating, and cramping -  while or after taking drugs with semaglutide as the active agent - we strongly advise you to call your doctor immediately. Semaglutide is the generic name for brands like Ozempic, Wegovy, and Rybelsus. The drugs were developed by Novo Nordisk and approved for use in the US.

Ozempic and Rybwlsus are not FDA-approved for weight loss, but doctors often prescribe them off-label for that purpose.

Studies link GLP-1 and RA drugs to bowel obstruction

Semaglutide Side Effects

Over the past years, the popularity of glucagon-like peptide 1 (GLP-1) receptor agonist (RA) medication, especially for Ozempic has skyrocketed. While the drug’s ability to help with weight management has been highly praised on social media platforms, there is a great deal of concern regarding potential side effects.

In October 2023, the Journal of the American Medical Association examined adverse events associated with GLP-1 RA drugs used for weight loss and published a letter in the October edition of JAMA Network. Researchers found increased risks of gastrointestinal adverse disorders, including bowel obstruction.

A recent study published by researchers from the University of British Columbia shows that compared to bupropion-naltrexone, patients on GLP-1 agonist drugs present a 4.22 times higher risk of bowel obstruction.

Individuals struggling with semaglutide side effects sued the manufacturer

Novo Nordisk, the manufacturer of Ozempic, Rybelsus, and Wegovy, was named as a defendant in several product liability lawsuits.

Although it denies blame, plaintiffs claim the drug manufacturer "failed to warn" users of the potential gastrointestinal risks involved including bowel obrstuction.

Currently, lawyers all over the US are investigating hundreds of inquiries from people struggling with semaglutide side effects.

Legal assistance in filing  your Ozempic/Wegovy/Rybelsus claim

If you have been diagnosed with bowel obstruction after using Ozempic, Wegovy, or Rybelsus please do not hesitate to contact our attorneys. Our team of experts will thoroughly evaluate your case to determine whether you can file a claim and obtain financial compensation from the liable manufacturer. We will do everything possible to make the legal process as simple and stress free as possible for you. To initiate the legal process you need to provide us with evidence of you using Ozempic, Wegovy, or Rybelsus and your medical records with bowel obstruction diagnosis. After careful assessment, we will let you know if you are eligible to file a claim.